Volume : 12, Issue : 06, June – 2025

Title:

EVALUATION OF ANTI-INFLAMMATORY ACTIVITY OF METHANOLIC EXTRACT OF COSMOS SULPHUREUS PLANT BY USING IN VIVO STUDIES

Authors :

Asif rasheed*, Masuma Begum Laskar, Mohd Amir Khan, Mohammed Asfander Ali, Munazza Fatima, Farhat Unnisa Begum

Abstract :

Inflammation is a complex biological response to harmful stimuli, often associated with various chronic diseases. The present study aimed to evaluate the anti-inflammatory activity of the methanolic extract of Cosmos sulphureus seeds using in vivo models. The extract was prepared through Soxhlet extraction, and preliminary phytochemical screening revealed the presence of flavonoids, alkaloids, tannins, and phenolic compounds-known for their anti-inflammatory properties. Wistar albino rats were divided into groups and subjected to carrageenan-induced paw edema and cotton pellet-induced Dextran-Induced Paw Edema, Formaldehyde-Induced The methanolic extract was administered in graded doses (100, 200, and 400 mg/kg body weight), and its effect was compared with a standard drug (diclofenac sodium). Results showed a dose-dependent and significant (p < 0.05) reduction in paw edema and granuloma formation, indicating potent anti-inflammatory activity. The findings suggest that Cosmos sulphureus seed extract possesses promising anti-inflammatory potential, likely due to its phytoconstituents, and may serve as a natural alternative for managing inflammatory conditions.
Keywords: Anti-Inflammatory, Cosmos sulphureus, Nonsteroidal, inflammation

Cite This Article:

Please cite this article in press Asif Rasheed et al., Evaluation Of Anti-inflammatory Activity Of Methanolic Extract Of Cosmos Sulphureus Plant By Using In Vivo Studies.., Indo Am. J. P. Sci, 2025; 12(07).

Number of Downloads : 10

References:

1. Artis, D.; Spits, H. The biology of innate lymphoid cells. Nature 2015, 517, 293–301.
2. Isailovic, N.; Daigo, K.; Mantovani, A.; Selmi, C. Interleukin-17 and innate immunity in infections and chronic inflammation. J. Autoimmun. 2015, 60, 1–11.
3. Pedraza-Alva, G.; Pérez-Martínez, L.; Valdez-Hernández, L.; Meza-Sosa, K.F.; Ando-Kuri, M. Negative regulation of the inflammasome: Keeping inflammation under control. Immunol. Rev. 2015, 265, 231–257.
4. Lucas, S.M.; Rothwell, N.J.; Gibson, R.M. The role of inflammation in CNS injury and disease. Br. J. Pharmacol. 2006, 147, S232–S240.
5. Rock, K.L.; Lai, J.J.; Kono, H. Innate and adaptive immune responses to cell death. Immunol. Rev. 2011, 243, 191–205.
6. Fernandes, J.V.; Cobucci, R.N.; Jatobá, C.A.; Fernandes, T.A.; de Azevedo, J.W.; de Araújo, J.M. The role of the mediators of inflammation in cancer development. Pathol. Oncol. Res. 2015, 21, 527–534.
7. Heppner, F.L.; Ransohoff, R.M.; Becher, B. Immune attack: The role of inflammation in Alzheimer disease. Nat. Rev. Neurosci. 2015, 16, 358–372.
8. Loane, D.J.; Kumar, A. Microglia in the TBI brain: The good, the bad, and the dysregulated. Exp. Neurol. 2016, 275, 316–327.
9. Waisman, A.; Liblau, R.S.; Becher, B. Innate and adaptive immune responses in the CNS. Lancet Neurol. 2015, 14, 945–955.
10. Vignali, D.A.; Kuchroo, V.K. IL-12 family cytokines: immunological playmakers. Nat. Immun. 2012, 13, 722–728.
11. Montgomery, S.L.; Bowers, W.J. Tumor necrosis factor-alpha and the roles it plays in homeostatic and degenerative processes within the central nervous system. J. Neuroimmune. Pharmacol. 2012, 7, 42–59.
12. Zelová, H.; Hošek, J. TNF-α signalling and inflammation: interactions between old acquaintances. Inflamm. Res. 2013, 62, 641–651.
13. Fenton, M.J. Review: Transcriptional and post-transcriptional regulation of interleukin 1 gene expression. Int. J. Immunopharmacol. 1992, 14, 401–411.
14. Rider, P.; Carmi, Y.; Voronov, E.; Apte, R.N. Interleukin-1α. Semin. Immunol. 2013, 25, 430–438.
15. Langrish, C.L.; McKenzie, B.S.; Wilson, N.J.; de Waal Malefyt, R.; Kastelein, R.A.; Cua, D.J. IL-12 and IL-23: master regulators of innate and adaptive immunity. Immunol. Rev. 2004, 202, 96–105.
16. Duvallet, E.; Semerano, L.; Assier, E.; Falgarone, G.; Boissier, M.C. Interleukin-23: A key cytokine in inflammatory diseases. Ann. Med. 2011, 43, 503–511.
17. Sabat, R. IL-10 family of cytokines. Cytokine Growth Factor Rev. 2010, 21, 315–324.
18. Ng, T.H.; Britton, G.J.; Hill, E.V.; Verhagen, J.; Burton, B.R.; Wraith, D.C. Regulation of adaptive immunity; The role of interleukin-10. Front. Immunol. 2013, 31, 129.
19. Kwilasz, A.J.; Grace, P.M.; Serbedzija, P.; Maier, S.F.; Watkins, L.R. The therapeutic potential of interleukin-10 in neuroimmune diseases. Neuropharmacology 2015, 96, 55–69.
20. Goetzl, E.J.; An, S.; Smith, W.L. Specificity of expression and effects of eicosanoid mediators in normal physiology and human diseases. FASEB J. 1995, 9, 1051–1058.
21. Leff, J.A.; Busse, W.W.; Pearlman, D.; Bronsky, E.A.; Kemp, J.; Hendeles, L.; Dockhorn, R.; Kundu, S.; Zhang, J.; Seidenberg, B.C.; et al. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N. Engl. J. Med. 1998, 339, 147–152.
22. Peters-Golden, M.; Henderson, W.R. Leukotrienes. N. Engl. J. Med. 2007, 357, 1841–1854.
23. Zhao, J.; Quyyumi, A.A.; Patel, R.; Zafari, A.M.; Veledar, E.; Onufrak, S.; Shallenberger, L.H.; Jones, L.; Vaccarino, V. Sex-specific association of depression and a haplotype in leukotriene A4 hydrolase gene. Psychosom. Med. 2009, 71, 691–696.
24. Moncada, S.; Bolanos, J.P. Nitric oxide, cell bioenergetics and neurodegeneration. J. Neurochem. 2006, 97, 16 –1689.
25. Rayet, B.; Gélinas, C. Aberrant rel/nfkb genes and activity in human cancer. Oncogene 1999, 18, 6938–6947.
26. Oeckinghaus, A.; Hayden, M.S.; Ghosh, S. Crosstalk in NF-κB signaling pathways. Nat. Immunol. 2011, 12, 695–708.
27. Ling, J.; Kumar, R. Crosstalk between NFkB and glucocorticoid signaling: A potential target of breast cancer therapy. Cancer Lett. 2012, 322, 119–126.
28. Khalifa, A.B. Herbs: Nature’s Pharmacy, 1st ed.; Arab Cultural Center: Casablanca, Morocco, 2004; pp. 286–288.
29. Siemiatycki J and Campbell S. Non-response bias and early versus all responders in mail and telephone surveys. Am J Epidemiol 1984; 120: 291-301
30. O’Toole BI, Battistutta D, Long A and Crouch K. A comparison of costs and data quality of three health survey methods: Mail, telephone and personal home interview. Am J Epidemiol 1986; 124: 317-328
31. Willett WC. Nutritional Epidemiology. 2nd Ed. Oxford University Press, 1998 .
32. Florey HW, 1970. Inflammation In: General Pathology. (ed. Lloyd Luke) Medical Books Ltd. London, p. 22.
33. Gurib-Fakim A, 2006. Review Medicinal plants: Traditions of Yesterday and drugs of tomorrow. Mol. Aspect. Med., 27: 1- 93.
34. Mallavadhani UV, Panda AK, Rao YR, 1998. Pharmacology and chemotaxonomy of Diospyros. Phytochem., 49: 901-951.
35. Karou D, Savadogo A, Canini A, Yameogo S, Montesano C, Simpore J, Colizzi V, Traore AS, 2006. Antibacterial activity of alkaloids from Sida acuta. Afri. J. Biotech., 5: 195-200.
36. Ghisalberti EL, 2000. Review – Lantana camara L. (Verbenaceae). Fitoterapia, 71: 467-486.
37. Neha Mohan PV, Suganthi V, Gowri S. Evaluation of anti-inflammatory activity in ethanolic extract of Coriandrum sativum L. using carrageenan induced paw oedema in albino rats. Der Pharma Chemica. 2013; 5: 139-143.
38. Hayllar J, Macpherson A, Bjarnason I. Gastroprotection and nonsteroidal antiinflammatory drugs. Drug Safe. 1992; 7: 86-105.
39. Ament PW, Childers RS. Prophylaxis and treatment of NSAID-induced gastropathy. Am Fam Phys. 1997; 55: 1323-1326.
40. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000; 284: 1247-1255.
41. Winter, C. A., Risley, E. A., & Nuss, G. W. (1962).Carrageenin-induced edema in hind paw of the rat as an assay for anti-inflammatory drugs.Proceedings of the Society for Experimental Biology and Medicine, 111(3), 544–547.
42. Harborne, J. B. (1998). Phytochemical Methods: A Guide to Modern Techniques of Plant Analysis (3rd ed.). Springer.
43. inter, C.A., Risley, E.A., & Nuss, G.W. (1962). Carrageenin-induced edema in hind paw of the rat as an assay for anti-inflammatory drugs. Proceedings of the Society for Experimental Biology and Medicine, 111(3), 544–547.
44. Swingle, K.F., & Shideman, F.E. (1972). Phases of the inflammatory response to subcutaneous implantation of a cotton pellet and their modification by certain anti-inflammatory agents. Journal of Pharmacology and Experimental Therapeutics, 183(1), 226–234.
45. Di Rosa, M., Giroud, J.P., & Willoughby, D.A. (1971). Studies of the mediators of the acute inflammatory response induced in rats in different sites by carrageenan and by dextran. Journal of Pathology, 104(1), 15–29.
46. Greenwald, R.A. (2001). Animal models for evaluation of arthritic drugs. Methods in Molecular Medicine, 51, 209–216.